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Background: Abdominal aortic aneurysms (AAA) are caused by inflammatory processes in the wall of the aorta resulting
in degradation of structural proteins. This inflammatory process is mediated, in part, by cytokines, and interleukin-10
(IL-10) is a predominately anti-inflammatory cytokine. A single nucleotide polymorphism in the promoter region of the
IL-10 gene that affects transcription has been associated with AAA in a small study. The aim of this study was to
determine whether this polymorphism is associated with AAA and also examine its effect on the growth of small AAA.
Methods and Results:A case control study was performed. A total of 389 patients with AAA and 404 healthy controls were
recruited. IL-10-1082 polymorphisms were determined by polymerase chain reaction-based methods. In the case of
patients with small AAA (<5.5 cm), serial size measurements were recorded to determine mean growth rate. There was
a statistically significant difference both in allele and genotype frequencies between the case and control groups with the
IL-10-1082 ‘A’ allele being more common in the AAA group (P  .006). In the AAA group, genotype frequencies were
as follows: GG 84, GA 201, and AA 104. In the control group, the genotype frequencies were GG 118, GA 205, and AA
81. The odds ratio for the ‘A’ allele as a risk factor for AAA was 1.50 (95% confidence interval 1.09 to 2.07). Regression
modeling revealed that the IL-10-1082 genotype was, however, not independently associated with AAA if age, tobacco
use, hypertension, and history of coronary or peripheral artery disease was taken into account. There was a trend towards
lower plasma IL-10 level in IL-10 AA carriers, but the IL-10 ‘A’ allele did not have any discernible effect on the growth
of small AAA.
Conclusions: This study demonstrates that the IL-10-1082 ‘A’ allele is associated with AAA, although this association is
likely to be secondary to an association between IL-10-1082 genotype and other markers of cardiovascular disease rather
than AAA per se. ( J Vasc Surg 2007;46:687-93.)Abdominal aortic aneurysms are characterized by the
destruction of medial elastin,1 increased collagen turn-
over,2 apoptotic loss of smooth muscle cells,3 and infil-
tration of chronic inflammatory cells.4 The structural
integrity of the aortic wall depends primarily on collagen
and elastin, and the degenerative changes seen in AAAs
are accompanied by increased production of several
members of the matrix metalloproteinase (MMP) family.
The activity of MMPs is partly controlled by specific
tissue inhibitors of MMPs (TIMPs),5 and an imbalance
of MMPs and TIMPs is thought to result in uncontrolled
destruction of elastin and collagen leading to aneurysm
formation.6
Tissue macrophages are the principal source of
MMPs in the aneurysm wall and form part of the chronic
inflammatory infiltrate.7 The production of MMPs is
regulated by cytokines, and both pro- and anti-inflam-
matory cytokines have been identified in the aneurysm
wall. In particular, one small study found increased levels
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doi:10.1016/j.jvs.2007.06.025of interleukin (IL)-10 in the aortic wall of patients with
AAAs compared with aortic occlusive disease.8 In a
similar study, Shteinberg9 found that patients with AAA
had significantly higher levels of the pro-inflammatory
cytokines TNF- and IL-1 than those with occlusive
aortic disease. These inflammatory processes may also
mediate the growth of small aneurysms.
Many cytokine genes contain polymorphic sites but
only a small number of these polymorphisms have been
shown to affect cytokine gene transcription in vitro. The
IL-10 gene contains a single nucleotide polymorphism
(SNP) at position -1082 in relation to the start codon.
The bases present at these sites are either guanine (G) or
adenine (A). The presence of an ‘A’ allele at -1082 results
in a 25% reduction in IL-10 production by lympho-
cytes.10 The IL-10-1082 ‘A’ allele has been shown to be
associated with several chronic inflammatory diseases
such as systemic lupus erythematosis,11 rheumatoid ar-
thritis,12 and juvenile rheumatoid arthritis.13 Given the
role of chronic inflammation in the pathogenesis of AAA
it is feasible that the IL-10 polymorphism may have a
role in the development and growth of AAAs. We have
previously identified in a pilot study that the IL-10-1082
‘A’ allele is more common in patients with AAA com-
pared with unscreened, age-matched controls.14 The
aim of this study was to investigate the role of the
IL-10-1082 genotype in a definitive, appropriately pow-
ered and screened replication group, and, in addition,
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of small AAA.
METHODS
A case-control study was performed. Cases with AAA
were recruited from the regional AAA screening program,
the vascular outpatient clinics and the vascular admissions
unit of a university teaching hospital. Controls were re-
cruited from the same AAA screening program, and the
general surgical unit of the same hospital. All cases and
controls were screened for AAA by either ultrasonography
or computed tomography. AAA was defined as abdominal
aortic diameter3 cm. Both male and female subjects were
included in the study. No participants recruited in our
previous study14 were included in this study group. Demo-
graphic and phenotypic data (age, gender, smoking history,
family history of AAA, hypertension, ischemic heart disease,
previous myocardial infarction, previous coronary artery
bypass grafting, previous cerebro-vascular disease, periph-
eral vascular disease, diabetes mellitus, chronic airways dis-
ease, or previous cancer) were recorded for each partici-
pant.
Blood samples were taken from each participant, cen-
trifuged, and the white cell layer stored at 80oC prior to
DNA extraction using a commercially available kit utilizing
the salting out method (Puregene, Gentra Systems Inc.,
Minneapolis, Minn). The IL-10-1082 genotype was deter-
mined by induced heteroduplex genotyping (IHG) as de-
scribed previously.14,15 Briefly, polymerase chain reaction
(PCR) mixes (25 l) contained 2.5 l of either DNA (100
ng/l) or heteroduplex generator (0.5 ng/l), 8 M each
deoxy-nucleotide tri-phosphate (dNTP), 5 M of each
forward and reverse primers, 0.25 units Taq polymerase, 1
 2.5 l Taq polymerase buffer (Sigma Aldrich, Poole,
UK) and 2.5 mM magnesium chloride (MgCl2) in hetero-
duplex generator reaction or 1.5 mM MgCl2 in each reac-
tion using patient DNA. PCR parameters, optimised for a
Perkin Elmer 480 Thermal Cycler (Perkin Elmer,
Waltham, Mass.), were an initial denaturation at 95oC for 5
minutes, followed by 30 cycles of denaturation at 95oC for
1 minute, annealing at 57oC for 1 minute, and extension at
72oC for 1 minute, with a final extension at 72oC for 5
minutes.
Following the initial PCR step, equal volumes (12 l)
of genomic DNA and heteroduplex generator amplicons
were mixed, heated to 95oC for 5 minutes, and then
allowed to cool to 45oC over 25 minutes to allow DNA
heteroduplex formation. Heteroduplexes were stained with
ethidium bromide solution (Sigma, UK) and resolved on
15% TBE polyacrylamide minigels (27.5:1 acrylamide:bis,
Bio-Rad, Hercules, Calif) run for 3 hours at a constant 100
V. Gels were visualised using ultraviolet light.
In a subgroup where samples could be transported
back to the laboratory according to the experimental
protocol (on ice and within one hour of sampling) and
where the subjects were at rest in an outpatient setting
(ie, nonperi- or postoperative cases/controls), plasma
IL-10 levels were determined by ELISA (Biosource,Paisley, UK) (Intra-assay coefficient of variation 10.1%,
inter-assay coefficient of variation 10.3%). All of these
study participants were those attending outpatient clin-
ics, and all of those with AAA were preoperative cases. To
determine AAA growth rates and to determine whether
IL-10-1082 genotype had any effect on AAA growth,
cases identified with small AAA (3-5.5 cm) or those
unsuitable for surgery were followed up by serial ultra-
sonography at the following intervals depending on the
aneurysm diameter: 12 months if 4 cm, 6 months if 4
cm to 5 cm, and 3 months if 5 cm. In addition,
historical data detailing previous AAA size was recorded
for each patient with an AAA where this had been
assessed.
Separate power calculations were performed using the
results from our previous study14 to ensure 80% power to
detect differences in both IL-10-1082 allele and genotype
frequency between the case and control groups (alpha 
0.001). These calculations determined that 290 cases and
290 controls would be required to detect the same differ-
ence in allele frequency as previously observed and 314 in
each group for the purposes of detecting differences in
genotype frequency.16
Tests for deviance from Hardy-Weinberg equilibrium
and comparisons between genotype frequency in the case
and control groups was determined using binary logistic
regression. Binary logistic regression was also used to con-
struct separate models for IL-10 allele and genotype as a
risk for AAA adjusted for age and other recorded patient
demographics. Covariates were included in the model if
they had a statistically significant effect (alpha  0.05).
IL-10 concentrations were compared between groups us-
ing one-way ANOVA and Student t-test. Mean AAA
growth rates were compared by Student t-test and
ANOVA. All statistical tests were carried out using SPSS
v12.0 (SPSS Inc., Chicago, Ill).
Ethical approval for the study was obtained from the
Leicestershire Research Ethics Committee, and each partic-
ipant consented to their inclusion in the study.
RESULTS
In total, 793 participants were included in the study.
The AAA group consisted of 389 individuals with median
age of 71 years (range 52 years to 94 years) and median
aortic diameter of 5.3 cm (range 3.0 cm to 12 cm). One
hundred eight (27.7%) of the patients in the AAA group
had previously undergone AAA repair; 404 control patients
with a median age of 65 years (range 52 years to 94 years)
and median aortic diameter of 1.8 cm (range 1.4 cm to
2.4 cm) were recruited. Demographic data for both groups
are shown in Table I. Hypertension, smoking, ischemic
heart disease, and chronic obstructive pulmonary disease
were more common in the AAA group who were also older
than the control group.
IL-10-1082 allele/genotype frequencies. Both AAA
and control groups were in Hardy-Weinberg equilibrium.
Genotype and allele frequencies are shown in Table II.
There was a statistically significant difference both in allele
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groups with the IL-10-082 ‘A’ allele being more common
in the AAA group (P  .014). The odds ratio for the
IL-10-1082 ‘A’ allele as a risk for AAA was 1.50 (95%
confidence interval 1.09 to 2.07). Each additional ‘A’ allele
had an increasing effect on the odds of AAA. The ‘GA’
genotype was associated with an odds ratio of 1.38 (95%
confidence interval 0.98 to 1.94, P  .07), and the odds
ratio for the ‘AA’ genotype was 1.76 (95% confidence
interval 1.21 to 2.70, P  .004).
To adjust for the effect of the differing demographics
and ages between the case and control groups a binary
logistic regression model was developed, initially inputting
all variables into the model and subsequently rejecting
those that failed to reach statistical significance (ischemic
heart disease, previous cerebrovascular accident, diabetes,
cancer, chronic obstructive pulmonary disease, and history of
myocardial infarction). The results are shown in Table III.
Table I. Numbers and percentages of cases and controls
with associated previously diagnosed pathology
Control (n  404) AAA (n  389)
N Percentage n Percentage
Female 9 2% 34 9%
Male 395 98% 355 91%
Age group (years):
50-59 2 0% 11 3%
60-69 338 84% 156 41%
70-79 44 11% 168 43%
80	 20 5% 54 13%
Current smoker 57 14% 97 25%
Prior smoker 266 66% 363 93%
Family history 11 3% 17 4%
Hypertension 179 44% 282 73%
IHD 63 16% 121 31%
MI 45 11% 93 24%
CABG 18 4% 49 13%
CVA 33 8% 61 16%
PVD 23 6% 91 23%
Diabetes 37 9% 31 8%
Cancer 29 6% 27 7%
COPD 32 8% 47 12%
IHD, Ischemic heart disease; MI, myocardial infarction; CABG, coronary
artery bypass graft; CVA, stroke; PVD, peripheral vascular disease; COPD,
chronic obstructive pulmonary disease.
Table II. Genotype and allele frequencies in the AAA
and control groups
Control (n  404) AAA (n  389)
P value*n Percentage N Percentage
GG 118 29% 84 21% P  .016
GA 205 51% 201 52%
AA 81 20% 104 27%
G allele 441 55% 369 47% P  .014
A allele 367 45% 409 53%
*Binary logistic regression.This model demonstrated that the effect of IL-10 genotypebecame nonsignificant after adjusting for the demographic
differences between the case and control groups.
Plasma IL-10 concentration and genotype. One
hundred nineteen controls and 131 cases had plasma IL-10
levels assayed. There was no significant difference in IL-10
levels between these two groups. Those with AAA had a
mean IL-10 level of 0.802 pg/ml (95% confidence interval
0.615 pg/ml to 1.045 pg/ml), and those in the control
group 0.904 pg/ml (95% confidence interval 0.737 pg/ml
to 1.111 pg/ml) (P  .485, Student t-test) (Statistical
analysis was performed on log-transformed data but results
are presented as untransformed values). There was no sig-
nificant correlation between AAA size and IL-10 levels in
the case group (P  .34, Pearson correlation). There was
no difference in IL-10 levels across the three IL-10 geno-
types (P  .684, one way ANOVA) with IL-10 levels as
follows: ‘GG’ genotype 0.938 pg/ml (95% confidence inter-
val 0.703 pg/ml to 1.253 pg/ml, n  67), ‘GA’ genotype
0.853 pg/ml (95% confidence interval 0.651 pg/ml to 1.118
pg/ml, n  113), ‘AA’ genotype 0.767 pg/ml (95% confi-
dence interval 0.554 pg/ml to 1.061 pg/ml, n  70). The
presence of one or more ‘A’ alleles had no effect on plasma
IL-10 levels (P  .483, Student t-test) (GG genotype
0.938 pg/ml (95% confidence interval 0.703 pg/ml to
1.253 pg/ml, n  67), GA or AA genotype 0.819 pg/ml
(95% confidence interval 0.667 pg/ml to 0.993 pg/ml,
n  183).
Growth of small AAA. Of the 389 participants with
AAA, 178 had two or more serial measurements of aortic
diameter, thereby allowing expansion rate to be calculated
(966 total observations, median 5, total follow up 591.8
person-years). Mean growth rate was 0.267 cm/year (stan-
dard deviation 0.280 cm/y, range 0.00 cm/y to 2.40
cm/y). There was no statistically significant difference in
mean growth rate between the three different IL-10-1082
genotypes, however, there was a trend toward increasing
growth rate with increasing numbers of ‘A’ alleles
Table III. Results of binary logistic regression modeling
to adjust for the effect of covariates
P Odds ratio 95% CI
IL-10 AA (vs GG) .134 1.448 0.836 to 1.916
IL-10 GA (vs GG) .266 1.265 0.892 to 2.350
Male gender .003 3.616 1.535 to 8.517
Age .000 1.131 1.097 to 1.166
Current smoker .004 1.889 1.230 to 2.900
Prior smoker .000 7.458 4.316 to 12.886
Family history .002 4.340 1.736 to 10.849
Hypertension .000 2.205 1.547 to 3.143
Previous CABG .000 3.139 1.669 to 5.903
PVD .001 2.493 1.452 to 4.280
Model statistics: Beta  11.369 (SE 1.16, P  .001)
CABG, Coronary artery bypass graft; PVD, peripheral vascular disease.
Non-significant covariates excluded from model: ischemic heart disease,
previous cerebrovascular accident, diabetes, cancer, chronic obstructive
pulmonary disease, and history of myocardial infarction.present. The presence of either a G allele or ‘A’ allele at
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rate (Table IV).
DISCUSSION
This study demonstrates that the IL-10-1082 ‘A’ allele
is associated with AAA, although in terms of risk, tradi-
tional markers of aneurysmal disease (age, tobacco use)
have a much greater influence on the development of AAA
than this SNP. After controlling for age and other common
demographic factors, IL-10 genotype was no longer signif-
icantly associated with AAA. Neither IL-10-1082 genotype
nor the ‘A’ allele can be considered as a genetic marker for
AAA. Indeed, in the AAA group, 21% did not possess an ‘A’
allele at all, and in the control group, a similar proportion of
individuals were homozygous for the ‘A’ allele. It is more
likely, therefore, that IL-10 genotype is associated with one
of the other risk factors for AAA identified in this study
rather than directly with AAA (hypertension or coronary
artery disease for example).
The IL-10-1082 allele appeared to be associated with
AAA in a codominant manner, with each additional ‘A’
allele at this SNP associated with increasing risk of AAA.
This finding is in keeping with our previously reported
association of this SNP with AAA in a separate case-control
study group. There was no evidence that this SNP affected
circulating IL-10 levels and whilst there was a trend to-
wards accelerated growth of small AAA with each addi-
tional ‘A’ allele at this locus, this finding was not statistically
significant.
The IL-10-1082 ‘A’ allele has been shown to be associ-
ated with other diseases such as systemic lupus erythemato-
sis,11 rheumatoid arthritis,12 juvenile rheumatoid arthritis,13
renal cell carcinoma,17 prostate cancer,18 breast cancer,19
and malignant melanoma.20 Studies have been performed
to determine any association between urological malig-
nancy and AAA and whilst several case reports exist describ-
ing coexisting AAA and renal cell carcinoma21,22 studies
designed to determine whether these associations are true
have determined that these are chance findings alone rather
than a true association.23 None of the other diseases above
have been demonstrated to have any association with AAA
Table IV. Mean growth rates observed in patients with A
possession
n Mean growth rate (cm/y)
Genotype
GG 37 0.224
GA 99 0.270
AA 42 0.301
G allele
Present 136 0.257
Absent 42 0.301
A allele
Present 141 0.279
Absent 37 0.224
ANOVA, Analysis of variance.and, indeed, given the gender associations of both breastcancer and AAA, these two diseases in particular would
seem to be unlikely to be related.
To our knowledge, this is the largest single genetic
association study of AAA to date, almost double the size
of any previous study24 and one of the few studies that
has demonstrated significant findings in a replication
group, albeit not after multivariate analysis. The failure
of the multivariate analysis to demonstrate the same
associations seen in the preliminary study analysis and
our previous study is disappointing. The most obvious
conclusion is that there is no association between the
IL-10-1082 SNP and AAA, but discrepancies between
the demographic constitution of the case and control
groups, especially in terms of age, may have contributed
to this failure. The most obvious nonenvironmental
(fixed) difference between the two groups was age. We
believe that this is unlikely to have significantly contrib-
uted to the lack of findings. Every control participant in
this study had undergone ultrasonographic confirmation
that no AAA was present and similarly all in the case
group had confirmed AAA at the time they were re-
cruited into the study. The main reason for the difference
in ages was the large number of male controls aged 65
years (n 231) and 66 years (n 89) recruited from the
regional AAA screening program. This resulted in the
skewed age distribution of the controls. Data from AAA
screening programs demonstrates that very few of those
without AAA at this age go on to develop AAA in the
future.25 It is, therefore, unlikely that a significant num-
ber of these controls would go on to develop AAA and
“cross over” into the case group, and since genotype is
constant over time, the allele and genotype frequencies
of this group would remain consistent assuming that this
study population is a random sample of the whole pop-
ulation. Indeed, if the regression model is constructed
without including age as a covariate, not surprisingly,
IL-10 genotype becomes more significant with the odds
ratios for AAA of 1.53 (95% confidence interval 0.97 to
2.42 (P  .07)) for those with an AA genotype and an
odds ratio of 1.32 (95% confidence interval 0.89 to 1.94
rouped according to IL-10-1082 genotype and allele
Standard deviation P
0.235 .468 (ANOVA)
0.231
0.398
0.232 .375 Student t-test
0.398
0.290 .283 Student t-test
0.235AA g(P  0.17)) for those with an GA genotype.
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multivariate analysis obviously also contributes to the find-
ing that IL-10 genotype was not associated with AAA after
multivariate analysis. One solution to this problem would
have been to match cases and controls precisely for all
demographic factors; however, this would have led to two
main problems. First, recruitment into the study would
have taken several years and resulted in a noncontempora-
neous dataset. Second, this could have resulted in “over-
matching”, a phenomenon that occurs when case and
control groups are matched for variables that are related to
the disease in question.26 In this case, those variables (other
than the fixed variables age and gender) that were signif-
icant in the logistic regression model were smoking
history, family history of AAA, previous coronary artery
bypass graft, and peripheral vascular disease. All of these
could be seen to be associated with AAA, and it is likely
that they were significant in the regression model for that
very reason. This principally informs us that these factors
are more significantly associated with AAA than IL-10
genotype.
A further limitation of this study is the inclusion of
patients with both small AAA (less than 5 cm) and large
AAA (greater than 5 cm) together in the same analysis. It is
recognized that there are differences in the vascular biology
of the AAA wall between small and large AAA.27 It may be
that further association studies comparing controls, pa-
tients with small AAA, and patients with large AAA would
be able to determine the role of IL-10 at different stages of
AAA development, however, each separate group would
need to be of a sample size similar to the whole sample size
of this study.
There is clear evidence that genetics contribute to the
pathogenesis of AAA. Patients with first degree relatives
with AAA are at increased risk of AAA themselves.28-30
Previous studies examining potential candidate genes for
AAA have shown that a deletion/insertion in the angioten-
sin converting enzyme (ACE) gene that is associated with
elevated plasma ACE levels has been shown to be more
common in patients with AAA than in control groups.31,32
Other genetic polymorphisms that have been shown to be
associated with AAA are an estrogen receptor beta (ER)
single nucleotide polymorphism (SNP),33 a haem oxygen-
ase I (HOI) promoter dinucleotide repeat,34 a methylene
tetrahydrofolate reductase (MTHFR) SNP,35 a platelet
activating factor acetyl-hydrolase (PAFAH) SNP,36 a com-
mon chemokine receptor-5 (CCR-5) insertion/deletion,37
a matrix metallo-proteinase-9 (MMP-9) SNP,38 and two
tissue inhibitor of metallo-proteinase-1 (TIMP-1) SNPs.24
In addition, some genetic polymorphisms have been shown
to be associated with growth of small AAA but not neces-
sarily the presence of AAA per se.39
In the majority of the studies above the findings are
biologically plausible. An ACE promoter deletion associ-
ated with high plasma ACE levels is commoner in patients
with AAA and since high ACE leads to high angiotensin II,
and this is over-expressed in the wall of AAA, the authors
suggest that this may be a causal link.31,32 Patients withAAA have been shown to have a higher frequency of long
HOI promoter dinucleotide repeats, which impairs the
ability of cells to upregulate the production of HOI in
response to stimuli. This reduction in HOI which is an
antioxidant and anti-inflammatory was postulated by the
authors to be related to the inflammatory degradation of
the aortic wall in AAA.34 Elevated plasma homocysteine
levels have been shown to be associated with vascular
diseases such as AAA and a SNP in the MTHFR gene which
results in reduced MTHFR activity, thus, leading to high
levels of plasma homocysteine is more common in patients
with AAA.35
However, none of the above studies, including this one
have demonstrated a single genetic locus that could be used
as a marker for AAA. This suggests that there may be
multiple genetic factors that lead to an individual being
genetically predisposed to the development of AAA. The
pattern of inheritance of AAA is not precisely known and
various different models have been suggested. In a study of
41 patients with AAA from 16 families, Tilson40 found that
there were two probable modes of inheritance, a common
X-linked model and a rarer autosomal dominant model, but
stated that a multifactorial mode of inheritance was possi-
ble. Majumder41 studied 91 patients with AAA and using
segregation analysis found that a nongenetic model was not
possible and that autosomal recessive inheritance was the
most likely. Powell,42 Verloes,43 and van Keulen44 sug-
gested multifactorial, autosomal dominant, and autosomal
dominant with incomplete penetrance were the likely
modes of inheritance. The largest study to date, which
includes the authors of three of the previous studies42-44 as
coauthors and appears to include their subjects, is that by
Kuivaniemi.45 In this study, a total of 233 families with 653
documented AAA were examined and multiple differering
inheritance patterns were observed: autosomal dominant
(25%), autosomal recessive (72%), and autosomal domi-
nant with incomplete penetrance (3%). The authors sug-
gest that this demonstrates a multifactorial genetic mode of
inheritance for AAA.
The hypothesis that low IL-10 producer genotype is
associated with AAA is biologically plausible. IL-10 is
also a potent anti-inflammatory agent. It is feasible that
low IL-10 levels lead to disregulation of the proinflam-
matory cascades in the wall of the aorta and, thus, AAA
formation. Whilst candidate gene approaches such as in
this study and those discussed may go some way to
explaining the genetic pathogenesis of AAA it is likely
that the potential for this approach is limited in diseases
with multifactorial genetic pathogeneses. Currently, a
number of studies of complex genetic diseases utlilizing
whole genome association approaches are underway, and
if these initial experiments demonstrate this to be a
robust approach, then given the heritability of AAA,
which is similar to if not greater than some other com-
plex traits, it would be appropriate to move to this
approach in appropriately powered cohorts.
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